NCM USA launches a new era in PET Radiopharmaceutical Manufacturing

Share Article

NCM USA announced today its launch of a state-of-the-art PET (Positron Emission Tomography) radiopharmaceutical manufacturing center in the Bronx, NY.

NCM USA announced today its launch of a state-of-the-art PET (Positron Emission Tomography) radiopharmaceutical manufacturing center in the Bronx, NY.

Revolutionizing the existing manufacturing of PET, the NCM facility design incorporates full-scale automation, multi-compound processing capability, cGMP compliance, and built-in redundancy.

Using its proprietary automation and never-seen-before innovative technologies, NCM is currently producing clinically approved compounds. NCM's innovative design is also enabling investigational compound and radiochemical manufacturing, as well as research collaboration.

The super advanced twenty-first century design of the facility facilitates the production of specialty radioisotopes that are currently in short supply in the US.

The completion and successful launch of this facility has now opened the doors for building and opening several other similar production facilities.

"We are now in a position to replicate our success in the top markets in United States. Within next five years, our revolutionary footprint will be available to clinics, hospitals, and researchers in all major markets in the United States." said Anwer Rizvi, President of NCM.

“While the world of PET has changed, the PET industry continues to function in a single-compound processing, non-proprietary drug environment. With several applications in oncology, neurology, and cardiology, and a promising pipeline of new drugs, the manufacturing of PET products must advance to support multi-compound production in a cGMP compliant environment. We have created that revolution and now PET customers can have access to efficient, reliable, and quality radiopharmaceuticals. PET is growing and we are there to support its growth - both by revolutionizing the manufacturing of PET and enabling new compounds to enter the market. We have elevated the status of PET drug manufacturing to the level that the Pharma industry has enjoyed for many years,” Mr. Rizvi added.

For more information about NCM USA visit our website: http://www.ncm-usa.com or call (212) 718-2322
About NCM USA

NCM is a privately held manufacturer of Positron Emission Tomography (PET) radiopharmaceuticals. Its headquarters are located in Manhattan, New York, and its NYC manufacturing location is in the Bronx.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Perter Webner
NCM
212-719-2322
Email >

Al Naqvi
PlanClear Co.
703-421-2229
Email >
Visit website

Media